{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=18&sponsor=Celgene",
    "query": {
      "sponsor": "Celgene",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 797,
    "total_pages": 80,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=19&sponsor=Celgene&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=17&sponsor=Celgene&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T19:24:28.407Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01881230",
      "title": "Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Breast Tumor",
        "Breast Cancer",
        "Cancer of the Breast",
        "Estrogen Receptor- Negative Breast Cancer",
        "HER2- Negative Breast Cancer",
        "Progesterone Receptor- Negative Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer",
        "Triple-negative Breast Cancer",
        "Triple-negative Metastatic Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 191,
      "start_date": "2013-09-26",
      "completion_date": "2016-10-28",
      "has_results": true,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 64,
      "location_summary": "Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 57 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01881230"
    },
    {
      "nct_id": "NCT01611467",
      "title": "A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety and Pharmacokinetics in Healthy Volunteer Subjects"
      ],
      "interventions": [
        {
          "name": "CC-223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2012-06-01",
      "completion_date": "2012-07-01",
      "has_results": false,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01611467"
    },
    {
      "nct_id": "NCT01261403",
      "title": "Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "PDA001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vehicle Controlled Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celularity Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 26,
      "start_date": "2010-12",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2020-07-22",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 16,
      "location_summary": "Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01261403"
    },
    {
      "nct_id": "NCT02267707",
      "title": "Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Neoplasms",
        "Cholestasis"
      ],
      "interventions": [
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-05-27",
      "completion_date": "2016-02-10",
      "has_results": false,
      "last_update_posted_date": "2019-11-01",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Detroit, Michigan",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02267707"
    },
    {
      "nct_id": "NCT00997581",
      "title": "Apremilast Therapy for Acute Gouty Arthritis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Gout"
      ],
      "interventions": [
        {
          "name": "apremilast",
          "type": "DRUG"
        },
        {
          "name": "indomethacin SR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2010-04",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00997581"
    },
    {
      "nct_id": "NCT01902225",
      "title": "Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "T-Cell Lymphoma",
        "Cutaneous Lymphoma"
      ],
      "interventions": [
        {
          "name": "Istodax",
          "type": "DRUG"
        },
        {
          "name": "Doxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weiyun Ai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-03-04",
      "completion_date": "2020-04-11",
      "has_results": false,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Columbus, Ohio",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01902225"
    },
    {
      "nct_id": "NCT01997840",
      "title": "ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2014-03-01",
      "completion_date": "2024-02-29",
      "has_results": true,
      "last_update_posted_date": "2025-03-04",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01997840"
    },
    {
      "nct_id": "NCT02279394",
      "title": "E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoldering Myeloma",
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2014-12-11",
      "completion_date": "2022-01-26",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Brewer",
          "state": "Maine"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02279394"
    },
    {
      "nct_id": "NCT01986894",
      "title": "A Phase 1 QT Study in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Pharmacology, Healthy Volunteer Study"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 72,
      "start_date": "2013-10-18",
      "completion_date": "2013-12-02",
      "has_results": false,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01986894"
    },
    {
      "nct_id": "NCT03723135",
      "title": "Expanded Access for CC-486",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "CC-486",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-09-18",
      "last_synced_at": "2026-10-15T19:24:28.407Z",
      "location_count": 1,
      "location_summary": "Summit, New Jersey",
      "locations": [
        {
          "city": "Summit",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03723135"
    }
  ]
}